摘要
目的探讨聚乙二醇化干扰素α-2a治疗慢性乙型肝炎发生HBsAg转阴患者的临床及实验室指标特点,探索影响HBsAg转阴的相关因素。方法收集4年时间我院所有确诊的经聚乙二醇化干扰素α-2a治疗的慢性乙型肝炎患者共61例,建立病史资料库,并按人口学特征、患病情况、实验室指标、病毒学指标、免疫状态及相关影响因素等多项指标分别进行统计学处理。结果61例经聚乙二醇化干扰素α-2a治疗的慢性乙型肝炎患者中,HBsAg转阴患者5例,56例未发现HBsAg转阴。通过多因素Logistic回归分析得出:病毒基因型、年龄、病程、HBV DNA水平成为最有可能的相关影响因素。结论聚乙二醇化干扰素α-2a的抗病毒治疗能够使HBsAg转阴;治疗前根据相关因素进行疗效评估有一定的参考意义。
Objective To investigate the clinical and laboratory characteristics in the chronic hepatitis B patients whose HBsAg diverted negative after pegylated interferon α-2a treatment, and to explore the predictative factors of HBsAg negative. Methods The study included 61 chronic hepatitis B patients treated with pegylated interferon α-2a （180 μg/week, one year） in our hospital from 2005 to 2008, Data were collected and the database were constructed. The indexes of demographic features, pathogenetic conditions, laboratory data, virology data and the immune status and related factors were identified by using the multifactorial logistic regression analysis. Results Among the 61 patients, 5 had loss of HBsAg, while other 56 remained HBsAg positive status. Virus Genotype, age, course of disease, HBV DNA titer tend to be the most predictable factors. Conclusion Pegylated interferon α-2a induced HBsAg loss of chronic hepatitis B. Good candidates can result in a high likelihood of HBsAg seroconversion.
出处
《肝脏》
2009年第5期364-366,共3页
Chinese Hepatology
